Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Immunotherapy and Helminthic Therapy

Activation Immunotherapies

Adoptive T Cell Therapy Methodology

Adoptive T Cell Therapy Applications

Immunotherapy: The Future of Lung Cancer Treatment?

Suppression Immunotherapies

Immunotherapy: Past, Present and Future

Neoantigens' Role in Immunotherapy

Latest Immunotherapy News and Research

New off-the-shelf immunotherapy for metastatic kidney cancer could help improve outcomes

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment - all without the need to customize treatment for each individual patient.

29 Aug 2025

Researchers identify genetic toolkit to reprogram cells into immune sentinels

An international team led by researchers at Lund University in Sweden has identified the molecular tools needed to reprogram ordinary cells into specialized immune cells.

29 Aug 2025

Tumor microbiota identified as predictors of prognosis in gastrointestinal cancers

Microbes inside cancerous tumors can influence the spread of disease and the effectiveness of treatment. Those roles make them appealing targets for new therapies and offer ways to better predict risk.

28 Aug 2025

New NIH-funded project aims to turn rare HIV cures into broadly applicable immunotherapy

Nearly 20 years ago, a man named Timothy Ray Brown who was living with HIV and cancer, underwent two courses of stem cell transplantation to treat his acute myeloid leukemia.

28 Aug 2025

New advances offer hope in the fight against KRAS-driven pancreatic cancer

Accounting for nearly 90% of all pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of just 13%. Late-stage diagnosis, limited surgical options, and toxic chemotherapy regimens contribute to its poor outcomes.

28 Aug 2025

New method uncovers how extracellular vesicles impact immune response in cancer

Certain types of biochemical processes can impair the immune system's ability to recognize and kill cancer cells. Purdue University's W. Andy Tao and his associates have developed a new way to study these processes.

26 Aug 2025

Diabetes-altered blood particles suppress immune defense in breast cancer

People with type 2 obesity-driven diabetes tend to have more aggressive breast cancers, but no one knows exactly why.

26 Aug 2025

Mount Sinai researchers develop MARQO to revolutionize cancer tissue analysis

Scientists at the Icahn School of Medicine at Mount Sinai have developed a powerful new computational tool that could transform how cancer tissues are analyzed and help pave the way for more personalized treatments.

25 Aug 2025

New study uncovers a surprising mechanism of resistance to immunotherapy

A new international study led by researchers at Moffitt Cancer Center, the Karolinska Institutet and the University of Texas MD Anderson Cancer Center has uncovered a surprising mechanism of resistance to immunotherapy: cancer's ability to injure nearby nerves.

21 Aug 2025

Cancer cells break down nerve covers causing immune exhaustion and therapy resistance

Cancer cells can break down the protective covers around nerves, causing nerve injury that triggers chronic inflammation leading to immune exhaustion and eventual resistance to immunotherapy, according to new research from The University of Texas MD Anderson Cancer Center.

20 Aug 2025

AI model detects genetic changes in colorectal cancer from tissue images

An international, interdisciplinary research team led by Prof. Jakob N. Kather from the Else Kröner Fresenius Center (EKFZ) for Digital Health at TUD Dresden University of Technology analyzed seven independent patient cohorts from Europe and the USA using their newly developed AI model.

20 Aug 2025

HPV16 reprograms immune cells to weaken cancer defenses

The most common cancer-causing strain of human papillomavirus (HPV), HPV16, undermines the body's defenses by reprogramming immune cells surrounding the tumor, according to new research from the Keck School of Medicine of USC.

19 Aug 2025

Special robot hunts for the perfect cancer warriors

Cancer patients can regain full health with immunotherapy. Now researchers are hunting for the perfect immune cell with the help of a very special robot.

18 Aug 2025

Missing messenger RNA fragments unlock new immunotherapy targets in pediatric brain tumors

A new study, led by researchers at Children's Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that are missing in pediatric high-grade glioma tumors but not in normal brain tissues.

18 Aug 2025

Amino acid metabolism shapes the tumor immune microenvironment and therapy response

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources.

17 Aug 2025

Plasma proteomics study unlocks predictive biomarkers for TNBC immunotherapy

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option.

17 Aug 2025

Engineered CD40 antibody shrinks tumors and induces remission

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment.

14 Aug 2025

New computational tool enhances CAR T cell therapy for hard-to-treat cancers

A computational approach by St. Jude Children's Research Hospital scientists promises to make designing T cell-based immunotherapies that target two cancer-related antigens at the same time far easier and faster.

13 Aug 2025

New drug-releasing system eliminates tumors in 82% of high-risk bladder cancer patients

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.

13 Aug 2025

mRNA vaccine shows potent efficacy in gastric cancer

Gastric cancer is one of the leading causes of cancer-related mortality worldwide, and peritoneal metastasis, wherein the cancer spreads to the peritoneum or the lining of the abdominal cavity, represents the most common form of recurrence after gastric cancer surgery.

13 Aug 2025